Blackrock Neurotech develops implantable brain–computer interface technologies for long-term neural recording and control of external devices. The company is best known for the Utah Array, an intracortical microelectrode array designed to interface directly with cortical neurons. Its hardware platforms are used to capture high-resolution neural signals for research and clinical applications. Blackrock Neurotech operates within regulated medical and research environments rather than consumer markets.

The Utah Array consists of a dense grid of microelectrodes that penetrate the cortical surface to record and stimulate neural activity at the single-neuron level. These signals are transmitted to external processing systems where they can be decoded into actionable outputs. The technology supports chronic implantation, enabling stable neural recordings over extended periods. This architecture has been widely used to study neural function and to enable brain-controlled interfaces.

Blackrock Neurotech positions its technology for use in clinical research, neuroprosthetics development, and investigational BCI applications. The platform has supported brain-controlled devices for communication, movement, and assistive technologies, particularly in populations with paralysis. Its focus on long-term, high-fidelity neural interfacing reflects ongoing efforts to translate intracortical BCIs from research settings into durable clinical systems.